Journal of Hepatology
Volume 51, Issue 4 , Pages 628-631, October 2009

HCV reinfection studies and the door to vaccine development☆

  • Jason Grebely

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia
    • ,
  • David L. Thomas

      Affiliations

    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    • Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
    • ,
  • Gregory J. Dore

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 2 93850900; fax: +61 2 93850876.

published online 17 July 2009.

Associate Editor: J.G. McHutchison

Article Outline

 

Two decades have passed since the discovery of hepatitis C virus (HCV) in 1989 [1]. Despite a massively expanded understanding of the virus and rapidly improving treatments, there is still no effective vaccine to prevent new HCV infections. A central question in HCV vaccine development is whether long-lasting, sustained protective immunity against HCV can be achieved. Multiple chimpanzee and human studies have provided valuable insights into this question. However, depending on the interpretation of these studies, the door to vaccine development has variably been perceived as open or closed.

Approximately one-third of persons will spontaneously clear a primary HCV infection, while others will have a persistent infection marked by ongoing viremia. This outcome is determined by a partially understood complex set of virus–host interactions. The available evidence indicates that the timing, magnitude, and breadth of adaptive immune responses are important [2], [3], [4], [5], [6], [7], [8]. CD4+ T cells responses appear to be critical to coordinate effective immunity, which probably explains the higher rate of HCV persistence in HIV-infected persons with CD4+ lymphocyte depletion.

Spontaneous recovery from HCV infection indicates that successful immunity is possible. However, reinfection has been demonstrated in chimpanzee and human studies. In chimpanzees, reinfection with both homologous and heterologous viruses has been documented [9], [10]. Compared to primary infection, reinfection episodes have been associated with improved control of viral replication, an attenuated course of infection, and an increased likelihood of clearance [11], [12], [13], [14], [15], [16]. Following both homologous and heterologous viral rechallenge, reductions in the duration and magnitude of viremia when compared to the initial infection have also been observed [14], [15].

Chimpanzee studies have also provided unique insights into the nature of successful adaptive immunity. Rapid virological control upon reinfection is associated with HCV-specific T cell responses [13], [15], [16]. When CD4+ T cells were depleted in vivo prior to reinfection, persistent HCV infection ensued [17]. Similarly, CD8+ T cell depletion led to prolonged HCV viremia, which was only controlled once CD8+ T cells reappeared in the liver [16]. In this context, cross-genotype immunity has been documented [14], but persistence appears more likely in the setting of heterologous re-challenge [15]. Collectively, these data in chimpanzees suggest that immunity against HCV can be generated by initial infection.

In humans, HCV reinfection has also been documented in a variety of settings [18], [19], [20], [21], [22], [23]. Similar to what has been observed in chimpanzees, levels of HCV viremia following reinfection are lower, generally transient, and shorter in duration than compared to the initial infection [24], [25]. Participants followed through episodes of primary HCV infection, spontaneous clearance and subsequent reinfection have been described [25], [26], [27]. Aberle et al. reported two cases of reinfection following spontaneous clearance, both of whom also cleared reinfection [27]. In one of these cases, a strong antiviral Th1 response to NS3-4 was maintained at high levels [27]. In a study by Osburn et al., HCV reinfection was observed in 11 of 22 (50%) injection drug users (IDUs) with spontaneous HCV clearance [25]. Subsequent clearance of reinfection was observed in nine of 11 (83%). Both the duration and peak HCV viremia in the setting of reinfection were decreased when compared to initial infection. Further, among reinfected participants, an increased breadth in HCV-specific T cell and broadened neutralizing antibody responses were observed. Data from these human studies are consistent with chimpanzee studies and suggest that protective HCV immunity, albeit not sterilizing, does exist in humans.

There are also a growing number of epidemiologic cohort studies which have sought to evaluate HCV reinfection rates and implications for protective immunity [28], [29], [30], [31]. In this issue of the Journal, van de Laar et al. evaluated HCV reinfection and superinfection among participants with HCV seroconversion enrolled in a large, prospective cohort of drug users in Amsterdam, the Netherlands followed up at six monthly intervals during the period 1985–2005 [32]. By nature of their initial acquisition of HCV infection, the study participants represented persons at substantial risk for subsequent exposure to HCV. Using a standardized methodology for the virological testing of samples collected over the 20-year period, the investigators performed a detailed clinical and virological characterization of acute HCV infection and viremia that was detected after the acute phase, which they classified as superinfection when the virus detected in the blood changed (in someone with persistent primary infection) or as reinfection when viremia first appeared to be cleared before another new virus was detected in the blood.

Reinfection and superinfection were frequent among the 59 participants with HCV seroconversion, with 24 participants (39%) having multiple HCV infections during study follow-up. Among 24 participants with spontaneous HCV clearance of primary infection, HCV reinfection was subsequently observed in nine, while viremia remained negative over long-term follow-up in 14 participants, despite ongoing drug use in 50%. Reinfection could be confirmed in two of nine participants with HCV reinfection and the remaining seven cases were categorized as having probable reinfection, given that HCV RNA could not be sequenced from samples at either the initial (n=6) or reinfection (n=1) time points, likely due to low-level viremia at the time of sequencing. Following reinfection, viral persistence was observed in six of nine participants (two of which were co-infected with HIV infection). However, three of seven participants with HCV mono-infection demonstrated prolonged viral clearance, despite ongoing risk behaviors for HCV acquisition over long-term follow-up.

This important study by van de Laar and colleagues clearly demonstrates that HCV superinfection and HCV reinfection occur frequently among IDUs and that, with ongoing exposure, some who initially cleared develop persistent infection while others have prolonged viral clearance. This heterogeneity may be partially explained by early immune responses [2], [3], [4], [5], [6], [7], [8] and/or host genetic factors [33]. The observation that some individuals with the immunological capacity to clear initial infection develop viral persistence following reinfection provides further evidence that protective immunity against HCV is incomplete. Further, they observed a similar rate of reinfection among those with HCV clearance compared to the rate of infection in those previously uninfected. As the authors state in this paper, based on the incidence rate ratio in this study, it is tempting to imply that HCV protective immunity does not exist at all – that the door to HCV vaccine development is closed. However, is that conclusion justified?

Neither HCV infection of chimpanzees or humans confers sterilizing immunity, defined as absolute protection against reinfection. However, the primary goal of vaccination is to prevent chronic hepatitis C, which causes cirrhosis and hepatocellular cancer. Thus, the question is whether immunity can be achieved to protect against viral persistence.

The human studies that have attempted to answer this question all have limitations that explain differences in their outcomes. Notably, most limitations underestimate the degree of protective immunity. For example, differences in subject characteristics including age, ethnicity, risk behaviors and HIV status, may affect observed rates of primary and reinfection clearance. Especially crucial, the actual number of HCV exposures is unknown and proxies such as drug use practices are incomplete at best. While chimpanzee studies count exposures, human studies only count incidents of viremia. An implication of this limitation is that long HCV RNA testing intervals underestimate exposure and protective immunity because reinfection events are overlooked, while viral persistence (by definition) is not (Fig. 1). In a study with a relatively broad testing interval, such as in the study by van de Laar et al, cases of reinfection and clearance would have been missed (Fig. 1, panel A) leading to an apparent predominance of viral persistence (Fig. 1, panel C) and the interpretation that there was a lack of protective immunity. Further, the outcome of reinfection (clearance vs. persistence) is often not adequately characterized because the person was not studied again after reinfection was first noted, again creating overestimation of viral persistence (and lack of protective immunity) bias.

  • View full-size image.
  • Fig. 1. 

    Impact of sampling frequency on perceptions of reinfection outcome. Hypothetical virological profiles in (A) a participant with initial spontaneous HCV clearance, several HCV reinfection events with reduced duration and peak HCV viremia and subsequent spontaneous clearance of reinfection in each instance; (B) a participant with initial spontaneous HCV clearance, several HCV reinfection events with similar duration and peak HCV viremia and subsequent spontaneous clearance of reinfection in each instance; and (C) a participant with spontaneous HCV clearance and HCV reinfection with persistent viremia. Solid lines indicate HCV RNA levels (light grey shading indicates persistent viremia). HCV RNA assessment time points are indicated by vertical dotted lines. Legends indicate the hypothetical frequency of HCV RNA testing (in weeks), the number of viremic events that would be identified with such a hypothetical HCV RNA testing frequency and the apparent outcome of infection based on the last available time point for that HCV RNA testing frequency.

There are also limitations in the classification of persons as “reinfected” or “superinfected”. Studies of persons infected by transfusion have shown that viremia can be cleared for months and then return without another exposure [34]. In an IDU, this pattern would be called reinfection. If the virus evaluated at the second point was genetically distinct from that detected at the initial viremia, one might more confidently conclude there was reinfection. However, in careful studies of persons who received more than one HCV-contaminated blood transfusion the same pattern has been reported (donor A virus, an extended period with no detectable viremia, then donor B virus) [35].

So, which way is it? We believe the door to development of an HCV vaccine that protects against chronic infection remains open. Available data suggest that the goal is both possible yet difficult. Further studies are required to determine just how open that door is. Ideally, these studies should carefully capture primary infection and repeat events with frequent regular sampling and detailed risk assessments and detailed virologic and immunologic studies.

Perhaps more than any other lesson, the data from van de Laar et al. reveal the inordinately high risk of HCV infection among IDUs and the urgency of opening all available doors that might more effectively contribute to prevention of infection in this setting.

Back to Article Outline

Acknowledgements 

J.G. was supported by Post Doctoral Fellowships from the Canadian Institutes of Health Research and the National Canadian Research Training Program in Hepatitis C. G.D. was supported by a National Health and Medical Research Council Practitioner Fellowship.

Back to Article Outline

References 

  1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362
  2. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995;346:1006–1007
  3. Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis. 2000;181:1528–1536
  4. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000;191:1499–1512
  5. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996;98:706–714
  6. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395–1406
  7. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436:946–952
  8. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6:578–582
  9. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G. Immunity in hepatitis C infection. J Infect Dis. 1992;165:438–443
  10. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992;258:135–140
  11. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 2001;33:1479–1487
  12. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol. 2002;76:6586–6595
  13. Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol. 2003;77:4781–4793
  14. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol. 2004;78:1575–1581
  15. Prince AM, Brotman B, Lee DH, Pfahler W, Tricoche N, Andrus L, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis. 2005;192:1701–1709
  16. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197:1645–1655
  17. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302:659–662
  18. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet. 1994;343:388–390
  19. Tisone G, Baiocchi L, Orlando G, Palmieri GP, Pisani F, Rapicetta M, et al. Hepatitis C reinfection after liver transplantation in relation to virus genotype. Transplant Proc. 1999;31:490–491
  20. Proust B, Dubois F, Bacq Y, Le Pogam S, Rogez S, Levillain R, et al. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol. 2000;38:3125–3127
  21. Payen JL, Izopet J, Barange K, Puel J, Selves J, Pascal JP. [Hepatitis C virus reinfection after an intravenous drug injection]. Gastroenterol Clin Biol. 1998;22:469–470
  22. Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, Vidaud M, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut. 2003;52:900–902
  23. den Hollander JG, Rijnders BJ, van Doornum GJ, van der Ende ME. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. AIDS. 2005;19:639–640
  24. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88
  25. Osburn WO, Fisher BE, Dowd KA, Melendez G, Liu L, Ray SC, et al. Protective immunity afforded by clearance of naı¨ve HCV infection is associated with diminished secondary viremia and generation of new cellular immune responses during reinfection. In: Programs and abstracts of the 13th international symposium on viral hepatitis and liver disease; Washington, DC, USA. 2009.
  26. Aitken CK, Tracy SL, Revill P, Bharadwaj M, Bowden DS, Winter RJ, et al. Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user. J Clin Virol. 2008;41:293–296
  27. Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, et al. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol. 2006;36:24–31
  28. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet. 2002;359:1478–1483
  29. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat. 2007;14:413–418
  30. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology. 2006;44:1139–1145
  31. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology. 2008;48:1746–1752
  32. van de Laar TJW, Molenkamp R, van den Berg C, Schinkel J, Beld MGHM, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol. 2009;51:667–674
  33. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872–874
  34. Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat. 2008;15:120–128
  35. Laskus T, Wang LF, Radkowski M, Vargas H, Nowicki M, Wilkinson J, et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol. 2001;75:2059–2066

☆ The authors who have taken part in this study declared that they do not have anything to declare regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00460-7

doi:10.1016/j.jhep.2009.07.002

Refers to article:

  • Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam , 18 June 2009

    Thijs J.W. van de Laar, Richard Molenkamp, Charlotte van den Berg, Janke Schinkel, Marcel G.H.M. Beld, Maria Prins, Roel A. Coutinho, Sylvia M. Bruisten
    Journal of Hepatology October 2009 (Vol. 51, Issue 4, Pages 667-674)

Journal of Hepatology
Volume 51, Issue 4 , Pages 628-631, October 2009

Article Tools

* Image Usage & Resolution